Unstable genomes elevate transcriptome dynamics

International Journal of Cancer

Volumn 134, Issue 9, 2014, Pages 2074-2087

  Stevens, Joshua B ^a   Liu, Guo ^a   Abdallah, Batoul Y ^a   Horne, Steven D ^a   Ye, Karen J ^a   Bremer, Steven W ^a   Ye, Christine J ^a   Krawetz, Stephen A ^a   Heng, Henry H ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

cancer evolution; CCAs; clonal chromosome aberrations; genome chaos; karyotypic heterogeneity; NCCAs; non clonal chromosome aberrations; transcriptome dynamics

Indexed keywords

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL IMMORTALIZATION; CHROMOSOME NUMBER; GENE DOSAGE; GENETIC HETEROGENEITY; GENETIC STABILITY; GENOME ANALYSIS; KARYOTYPE; MUTATION; PRIORITY JOURNAL; RNA REPLICATION; SPECTRAL KARYOTYPING; TRANSCRIPTOMICS;

CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMAL INSTABILITY; EVOLUTION, MOLECULAR; GENE EXPRESSION PROFILING; GENOME, HUMAN; HUMANS; KARYOTYPE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TRANSCRIPTOME;

EID: 84896715917     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28531     Document Type: Article

References (56)

1. Chan SK, Griffith OL, Tai IT, et al. Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers. Cancer Epidemiol Biomarkers Prev 2008; 17: 543-52.
2. Van Haren R, Feldman D, Sinha AA,. Systematic comparison of nonmelanoma skin cancer microarray datasets reveals lack of consensus genes. Br J Dermatol 2009; 161: 1278-87.
3. Evan JP, Meslin EM, Marteau TM, et al. Genomics. Deflating the genomic bubble. Science 2011; 331: 861-2.
4. Venet D, Dumont JE, Detours V,. Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol 2011; 7: e1002240.
5. Nowell PC,. The clonal evolution of tumor cell populations. Science 1976; 194: 23-8.
6. Vogelstein B, Kinzler KW,. The multistep nature of cancer. Trends Genet 1993; 9: 138-41.
7. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100: 57-70.
8. Shaffer LG, Slovak ML, Campbell LJ,. ISCN 2009 an international system for human cytogenetic nomenclatureed. Karger, Basel, Switzerland, 2009.
9. Heng HH, Bremer SW, Stevens JB, et al. Chromosomal Instability (CIN): what it is and why it is crucial to cancer evolution. Cancer Met Rev, 2013; Epub ahead of print.
10. Heng HH, Stevens JB, Liu G, et al. Stochastic cancer progression driven by non-clonal chromosome aberrations. J Cell Physiol 2006; 208: 461-72.
11. Navin N, Kendall J, Troge J, et al. Tumour evolution inferred by single-cell sequencing. Nature 2011; 472: 90-4.
12. Stevens JB, Abdallah BY, Liu G, et al. Heterogeneity of cell death. Cytogenet Genome Res 2013; 139: 164-73.
13. Stevens JB, Abdallah BY, Horne SD, et al. Chromosomal instability and transcriptome dynamics in cancer. Cancer Met Rev, 2013; Epub ahead of print.
14. Ye CJ, Stevens JB, Liu G, et al. Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer. J Cell Physiol 2009; 219: 288-300.
15. Heng HH, Liu G, Stevens JB, et al. Decoding the genome beyond sequencing: the new phase of genomic research. Genomics 2011; 98: 242-52.
16. Heng HH,. The genome-centric concept: resynthesis of evolutionary theory. Bioessays 2009; 31: 512-25.
17. Heng HH, Stevens JB, Bremer SW, et al. Evolutionary mechanisms and diversity in cancer. Adv Cancer Res 2011; 112: 217-53.
18. Heng HH, Liu G, Stevens JB, et al. Genetic and epigenetic heterogeneity in cancer: the ultimate challenge for drug therapy. Curr Drug Targets 2010; 11: 1304-16.
19. Heng HH, Stevens JB, Bremer SW, et al. The evolutionary mechanism of cancer. J Cell Biochem 2010; 109: 1072-84.
20. Kaiser J,. Cancer genetics with an edge. Science 2012; 337: 282-84.
21. Zhu J, Pavelka N, Bradford WD, et al. Karyotypic determinants of chromosome instability in aneuploid budding yeast. PLoS Genet 2012; 8: e1002719.
22. Pavelka N, Rancati G, Zhu J, et al. Aneuploidy confers quantitative proteome changes and phenotypic variation in budding yeast. Nature 2010; 468: 321-25.
23. Blount ZD, Barrick JE, Davidson CJ, et al. Genomic analysis of a key innovation in an experimental Escherichia coli population. Nature 2012; 489: 513-8.
24. Gao C, Furge K, Koeman J, et al. Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations. Proc Natl Acad Sci U S A 2007; 104: 8995-9000.
25. Upender MB, Habermann JK, McShane LM, et al. Chromosome transfer induced aneuploidy results in complex dysregulation of the cellular transcriptome in immortalized and cancer cells. Cancer Res 2004; 64: 6941-9.
26. Wang RT, Ahn S, Park CC, et al. Effects of genome-wide copy number variation on expression in mammalian cells. BMC Genomics 2011; 12: 562.
27. Pollack JR, Sørlie T, Perou CM, et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A 2002; 99: 12963-68.
28. Bischoff FZ, Yim SO, Pathak S, et al. Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: aneuploidy and immortalization. Cancer Res 1990; 50: 7979-84.
29. Heng HH, Stevens JB, Lawrenson L, et al. Patterns of genome dynamics and cancer evolution. Cell Oncol 2008; 30: 513-4.
30. Galipeau PC, Li X, Blount PL, et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med 2007; 4: e67.
31. Fridman AL, Tang L, Kulaeva OI, et al. Expression profiling identifies three pathways altered in cellular immortalization: interferon, cell cycle, and cytoskeleton. J Gerontol A Biol Sci Med Sci 2006; 61: 879-89.
32. Cheadle C, Vawter MP, Freed WJ, et al. Analysis of microarray data using Z score transformation. J Mol Diagn 2003; 5: 73-81.
33. Gleichmann M, Zhang Y, Wood WH, III, et al. Molecular changes in brain aging and Alzheimer's disease are mirrored in experimentally silenced cortical neuron networks. Neurobiol Aging 2012; 33: 205 e1-18.
34. Storey JD,. A direct approach to false discovery rates. J R Stat Soc B 2001; 64: 479-98.
35. Kornblau SM, Tibes R, Qiu YH, et al. Functional proteomic profiling of AML predicts response and survival. Blood 2009; 113: 154-64.
36. Fridman AL, Tainsky MA,. Critical pathways in cellular senescence and immortalization revealed by gene expression profiling. Oncogene 2008; 27: 5975-87.
37. Heng HH, Bremer SW, Stevens JB, et al. Genetic and epigenetic heterogeneity in cancer: a genome-centric perspective. J Cell Phys 2009; 220: 538-47.
38. Venet D, Dumont JE, Detours V,. Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol 2011; 7: e1002240.
39. York H, Kornblau SM, Qutub AA,. Network analysis of reverse phase protein expression data: characterizing protein signatures in acute myeloid leukemia cytogenetic categories t(8;21) and inv(16). Proteomics 2012; 12: 2084-93.
40. Abdallah BY, Horne SD, Stevens JB, et al. Single cell heterogeneity: why unstable genomes are incompatible with average profiles, Cell Cycle 2013; E pub ahead of print.
41. Stevens JB, Abdallah B, Liu G, et al. Diverse system stresses: common mechanisms of chromosome fragmentation. Cell Death Dis 2011; 2: e178-e86.
42. Heng HH,. Elimination of altered karyotypes by sexual reproduction preserves species identity. Genome 2007; 50: 517-24.
43. Gorelick R, Heng HH,. Sex reduces genetic variation: a multidisciplinary review. Evolution 2011; 65: 1088-98.
44. Whibley C, Odell AF, Nedelko T, et al. Wild-type and Hupki (human p53 knock-in) murine embryonic fibroblasts: p53/ARF pathway disruption in spontaneous escape from senescence. J Biol Chem 2010; 285: 11326-35.
45. Williams BR, Prabhu VR, Hunter KE, et al. Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. Science 2008; 322: 703-9.
46. Yasaei H, Gilham E, Pickles JC, et al. Carcinogen-specific mutational and epigenetic alterations in INK4A, INK4B and p53 tumour-suppressor genes drive induced senescence bypass in normal diploid mammalian cells. Oncogene 2013; 32: 171-9.
47. Kuijjer ML, Rydbeck H, Kresse SH, et al. Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. Genes Chromosomes Cancer 2012; 51: 696-706.
48. Sheltzer JM, Torres EM, Dunham MJ, et al. Transcriptional consequences of aneuploidy. Proc Natl Acad Sci U S A 2012; 109: 12644-49.
49. Rancati G, Pavelka N, Fleharty B, et al. Aneuploidy underlies rapid adaptive evolution of yeast cells deprived of a conserved cytokinesis motor. Cell 2008; 135: 879-93.
50. Heng HH,. Biocomplexity: Challenging reductionism. In:, Sturmberg JP, Martin CC,. Handbook on Systems and Complexity in Health. New York: Springer 2013: 193-208.
51. Horne SD, Stevens JB, Abdallah BY, et al. Why imatinib remains an exception of cancer research. J Cell Physiol 2013; 228: 665-70.
52. Heng HH, Liu G, Stevens JB, et al. Karyotype heterogeneity and unclassified chromosomal abnormalities. Cytogenet Genome Res 2013; 2: 144-57.
53. Huang S,. Genetic and non-genetic instability in tumor progression: link between the fitness landscape and the epigenetic landscape of cancer cells. Cancer Metastasis Rev, 2013; Epub ahead of print.
54. Loven J, Orlando DA, Sigova AA, et al. Revisiting global gene expression analysis. Cell 2012; 151: 476-82.
55. Heng HH,. Missing heritability and stochastic genome alterations. Nat Rev Genet 2010; 11: 812-12.
56. Heng HH,. Genomics: HeLa genome versus donor's genome. Nature 2013; 501: 167-67.